Novel Bisphosphonate Formulation with Therapeutic Use in Osteoporosis

Description:

Market: There is a large market demand for therapeutic compounds addressing bone disease. Osteoporosis, osteitis deformans, or Paget?s disease, bone metastasis, multiple myeloma, and others result in bone fragility. It is noted that metastases to the bone occur in up to 75% of breast and prostate cancers. Of the above listed bone diseases, osteoporosis is a major indication with thirty-five million people in the seven major pharmaceutical markets (U.S., France, Germany, Italy, Spain, UK, and Japan) afflicted by osteoporosis. With this type of demand, it is not surprising that a recent analysis projects the 2006 bone disease therapeutic market will exceed $11.6 billion (MarketResearch.com, 2005).

 

Competitors and Current Problems: Bisphosphonates, a class of drugs that inhibits the resorption of bone, commands this market. While highly effective, bisphosphonates do have significant side effects. These include nausea, abdominal pain, loose bowel movements, irritation, and even ulcers of the stomach and esophagus. An additional problem is low bioavailability. Half of an administered dose of some bisphosphonates is cleared by the kidneys unused, with some compounds having only five percent bioavailability.


The Technology: A UTHealth scientist developed a novel class of bisphosphonates in a unique formulation. The new compounds demonstrate a 2- to 20-fold increased bioavailability depending on the compound. The increased bioavailability may lead to a less frequent dosing regimen. Further, the new compounds showed decreased gastrointestinal toxicity in pre-clinical studies. Specifically, gastric lesions were reduced 2 fold and gastric bleeding reduced 6 fold. The technology is subject to a strong patent position, which protects compositions, methods of manufacture, and methods of use to prevent and treat bone disease.


 

UTHealth Ref. No.: 2000-0013
Inventors: Dr. Lenard M. Lichtenberger
Patent Status: Issued U.S. Patent Nos. 6,943,155 and 7,354,912
License Available: world-wide; exclusive or non-exclusive

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Therapeutics
For Information, Contact:
Christine Flynn
Associate Director, Licensing and New Venture Development
University of Texas Health Science Center At Houston
Christine.Flynn@uth.tmc.edu
Inventors:
Keywords:
© 2020. All Rights Reserved. Powered by Inteum